06.22.16
Custom pharmaceutical development and manufacturing company IriSys has established a business development office in Shanghai. The office is staffed by business development manager, Leonard Shi.
IriSys says it has implemented a strategy to focus on Asia, bridging the gap between innovators there and access to the U.S. regulatory infrastructure and markets.
“In addition to our capabilities in formulation and novel drug delivery techniques, our FDA consulting services will be of great value to small to mid-sized Japanese and Chinese pharmaceutical companies that want to bring products to the U.S. for development,” said Gerald Yakatan, founder, chairman and chief executive officer, IriSys. “Our Shanghai office will help us develop business opportunities in China, Japan and other Asian countries."
IriSys was a finalist in the 2015 MetroConnect competition and the $25,000 in award monies contributed to this effort. The MetroConnect Prize is the flagship program of the Go Global San Diego Initiative that provides small and medium-sized enterprises (SMEs) the resources they need to engage in global markets.
IriSys says it has implemented a strategy to focus on Asia, bridging the gap between innovators there and access to the U.S. regulatory infrastructure and markets.
“In addition to our capabilities in formulation and novel drug delivery techniques, our FDA consulting services will be of great value to small to mid-sized Japanese and Chinese pharmaceutical companies that want to bring products to the U.S. for development,” said Gerald Yakatan, founder, chairman and chief executive officer, IriSys. “Our Shanghai office will help us develop business opportunities in China, Japan and other Asian countries."
IriSys was a finalist in the 2015 MetroConnect competition and the $25,000 in award monies contributed to this effort. The MetroConnect Prize is the flagship program of the Go Global San Diego Initiative that provides small and medium-sized enterprises (SMEs) the resources they need to engage in global markets.